Phase 3 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 80 years old, of any sex
- People who have not previously received treatment for their DLBCL (such as chemotherapy, targeted therapy, immunotherapy, or surgery aimed at the lymphoma), and who have achieved a complete response (meaning no detectable cancer) after 6 cycles of a standard chemotherapy combination called R-CHOP, confirmed by scans and other assessments
- People diagnosed with a specific type of blood cancer called Diffuse Large B-Cell Lymphoma (DLBCL) that tests positive for a protein called CD20, and who also have evidence of active or chronic hepatitis B virus (HBV) infection — people already on stable hepatitis B antiviral medication for at least 4 weeks before joining may also be considered
- People with a general health and activity level rated as 0, 1, or 2 on a standard medical scale (meaning broadly independent and able to carry out daily activities, with or without some limitations)
- People whose blood test results at screening meet certain minimum thresholds for red blood cells, white blood cells, platelets, kidney function, and liver function (confirm with trial site for specific values)
- People whose doctor estimates they have a life expectancy of at least 6 months
- People who are able to understand and willingly sign a consent form for the trial
Who may not be able to join:
- People who are pregnant, breastfeeding, or who are able to have children but are unwilling to use contraception
- People with a history of certain significant heart conditions, including irregular heart rhythms, heart attack within the past year, heart failure, or symptomatic coronary artery disease requiring medication
- People who have previously had an organ transplant
- People who received treatment for low blood cell counts (as a symptom-relief measure) within the 7 days before joining the trial
- People with active (ongoing) bleeding
- People with a history of, or current diagnosis of, blood clots, stroke, or related conditions
- People with an active infection, or who have had a persistent fever in the 14 days before joining the trial
- People who have not yet fully recovered (at least 6 weeks) from a major surgical procedure
- People with significantly abnormal liver or kidney function test results
- People with a mental health condition that would prevent them from giving informed consent
- People with a drug or alcohol dependency that could interfere with the trial results
- People whose lymphoma has spread to the brain or central nervous system
- People whom the trial doctor considers unsuitable for the study for any other reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ou Bai, PHD, The First Bethune Hospital of Jilin University
Phone: 15804302602
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-free survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.